Juno Therapeutics is a biopharma company developing novel cellular immunotherapies based on two distinct and complementary platforms: T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs) technologies.
Juno Therapeutics – next generation CAR technology
Juno Therapeutics is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno Therapeutics has shown compelling evidence of tumor shrinkage in clinical trials using multiple cell-based product candidates to address refractory B-cell lymphomas and leukemias. By re-engaging the body’s immune system to treat cancer, these cellular therapies have the potential to be effective regardless of the type of previous treatments and may avoid the long-term side effects associated with current treatments. Through genetic engineering, Juno Therapeutics inserts a gene for a particular CAR or TCR construct into the T cell enabling it to recognize cancer cells. To manufacture these therapeutic T cell product candidates, Juno harvests blood cells from a cancer patient, separates the appropriate T cells, activates them and inserts the gene sequence for the CAR or TCR construct into the cell’s DNA. Then these modified T cells are grown to the desired dose level. These modified T cells can be infused into the patient or frozen and stored for later infusion. Once infused, these T cells are designed to multiply when they encounter the targeted proteins and to kill the targeted cancer cells.
Juno Therapeutics is a biopharma company based in the USA. Juno Therapeutics’ Board of Directors is comprised of industry leaders with an outstanding track record of navigating novel science and building enduring companies: Hal Barron, Hans Bishop, Anthony Evnin, Richard Klausner, Robert Nelsen, Howard Pien, Marc Tessier-Lavigne and Mary Agnes Wilderotter. Juno’s Scientific Advisors are José Baselga, Jeff Bluestone and Larry Corey. And Juno Therapeutics brings together some of the world’s leaders in oncology, immunology, and cell therapy (Renier Brentjens, Phil Greenberg, Michael Jensen, Stan Riddell, Isabelle Rivière and Michel Sadelain). Juno is led by a Management Team with diverse backgrounds and talents, composed by Hans Bishop, Steve Harr, Mark Frohlich, Mark Gilbert, Ken Mohler, Elizabeth Smith, Barney Cassidy, Andy Walker and Robin Andrulevich.
More about Juno Therapeutics: https://junotherapeutics.com/